Group 1 - The core viewpoint of the news is that the Nasdaq Biotechnology Index (NBI) has shown resilience and growth amid rising expectations for interest rate cuts by the Federal Reserve, with the NBI increasing by 2.06% [1] - The Nasdaq Biotechnology ETF (513290) has experienced significant inflows, rising by 0.85% as of 10:58 AM on August 5, marking three consecutive days of net inflows over the past five trading days [1][3] - Key component stocks of the Nasdaq Biotechnology ETF have mostly risen, with Summit Therapeutics (SMMT) up over 8%, and other notable increases from Alnylam Pharmaceuticals (ALNY) and Regeneron Pharmaceuticals (REGN) [3][4] Group 2 - Vertex Pharmaceuticals (VRTX) reported a 2.19% increase in stock price with a trading volume of 1.07 billion, while Amgen (AMGN) rose by 1.70% with a trading volume of 695 million [4] - Vertex Pharmaceuticals is projected to have total revenue of $2.96 billion in Q2 2025, reflecting a 12% year-over-year growth, while its non-GAAP net profit for Q2 is expected to be $1.2 billion [6] - The Federal Reserve's interest rate cut expectations have increased significantly, with an 80% probability of a rate cut in September and a 50% chance of another cut in October, driven by weaker-than-expected non-farm payroll data [6][8] Group 3 - The Nasdaq Biotechnology Index (NBI) serves as a benchmark for global innovative pharmaceuticals, including top biotech companies listed on Nasdaq, and is weighted by market capitalization [12] - The Nasdaq Biotechnology ETF (513290) is the only ETF that focuses on global innovative pharmaceuticals, allowing investors to access leading biotech firms with a low entry point [12] - The combination of potential interest rate cuts, ongoing AI innovations, and increased merger and acquisition activity is expected to catalyze a new wave of growth in the biotech sector [12]